Interleukin-6 Blockade Abrogates Immunotherapy Toxicity and Promotes Tumor Immunity
Yared Hailemichael(The University of Texas MD Anderson Cancer Center), Adi Diab(Cleveland Clinic), Wei Lü(The University of Texas MD Anderson Cancer Center), Jared K. Burks(The University of Texas MD Anderson Cancer Center), Wai Chin Foo(The University of Texas MD Anderson Cancer Center), Jonathan L. Curry(The University of Texas MD Anderson Cancer Center), Cassian Yee(The University of Texas MD Anderson Cancer Center), Chrystia M. Zobniw(The University of Texas MD Anderson Cancer Center), Khalida Wani(The University of Texas MD Anderson Cancer Center), Patrick Hwu(Moffitt Cancer Center), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Alejandro Francisco‐Cruz, Brenda Melendez(The University of Texas MD Anderson Cancer Center), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Cara Haymaker(The University of Texas MD Anderson Cancer Center), Alexander J. Lazar(The University of Texas MD Anderson Cancer Center), Gregory Lizée(The University of Texas MD Anderson Cancer Center), Chantal Saberian(The University of Texas MD Anderson Cancer Center), Sühendan Ekmekçioglu(The University of Texas MD Anderson Cancer Center), Christine Spillson(The University of Texas MD Anderson Cancer Center), May Daher(The University of Texas MD Anderson Cancer Center), Mario L. Marques‐Piubelli(The University of Texas MD Anderson Cancer Center), Dai Ogata(Unknown), Roza Nurieva(The University of Texas MD Anderson Cancer Center), Yinghong Wang(Hangzhou Center for Disease Control and Prevention), Daniel H. Johnson(The University of Texas MD Anderson Cancer Center), Van Anh Trinh(University of Houston), Salah Eddine Bentebibel(Texas Medical Center), Luisa M. Solis(The University of Texas MD Anderson Cancer Center), Noha Abdel‐Wahab(The University of Texas MD Anderson Cancer Center), Sang Taek Kim(University of Houston), Hamzah Abu‐Sbeih(The University of Texas MD Anderson Cancer Center)
Cited by 24
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k